N-able reported its fourth quarter and full-year 2024 results, achieving an adjusted earnings per share (EPS) of $0.10, surpassing the $0.08 estimate. The company's revenue for the quarter was $116.5 million, exceeding the guidance of $113.77 million. N-able's net income stood at $3.3 million. Looking ahead, the company expects first quarter 2025 revenue to be between $115 million and $116 million, reflecting a year-over-year growth of approximately 1% to 2%. In contrast, Syndax Pharmaceuticals reported a fourth quarter 2024 GAAP EPS of $(1.10), missing the $(1.01) estimate, with sales of $7.68 million, significantly below the $85.91 million estimate. Okta's fourth quarter 2025 results showed an adjusted EPS of $0.78, beating the $0.74 estimate, and revenue of $682 million, which was above the $669.46 million estimate. The company noted a 13% year-over-year increase in revenue and subscription revenue. Okta also provided guidance for the first quarter 2026, projecting revenue between $678 million and $680 million, exceeding the $670.813 million estimate. Additionally, Dave reported an adjusted EPS of $2.04, significantly above the $0.42 estimate, with sales of $100.90 million, surpassing the $95.45 million estimate.